ReviewClinical & translational immunology2014
Clinical application of genetically modified T cells in cancer therapy.
Review in Clinical & translational immunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 108 citations in OpenAlex.
- A New Protein-Ligand Trapping System to Rapidly Screen and Discover Small-Molecule Inhibitors of PD-L1 from Natural Products.Molecules (Basel, Switzerland) · 2025Article
- Practical immunomodulatory landscape of glioblastoma multiforme (GBM) therapy.Journal of the Egyptian National Cancer Institute · 2024Review
- Adoptive T cell therapy for ovarian cancer.Gynecologic oncology · 2024Review
- Combination therapy for pancreatic cancer: anti-PD-(L)1-based strategy.Journal of experimental & clinical cancer research : CR · 2022Review
- Biomedical polymers: synthesis, properties, and applications.Science China. Chemistry · 2022Review
- Avidity optimization of a MAGE-A1-specific TCR with somatic hypermutation.European journal of immunology · 2021Article
- The Microbiome and Its Implications in Cancer Immunotherapy.Molecules (Basel, Switzerland) · 2021Review
- Developing C2-Aroyl Indoles as Novel Inhibitors of IDO1 and Understanding Their Mechanism of InhibitionFrontiers in chemistry · 2021Article
- Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer.Molecular therapy oncolytics · 2020Article
- Emerging CAR T cell therapies: clinical landscape and patent technological routes.Human vaccines & immunotherapeutics · 2020Article
- Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy.Journal of experimental & clinical cancer research : CR · 2020Review
- Myeloid-driven mechanisms as barriers to antitumor CD8Molecular immunology · 2020Review
- Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future.Frontiers in immunology · 2020Review
- 4,5-Disubstituted 1,2,3-triazoles: Effective Inhibition of Indoleamine 2,3-Dioxygenase 1 Enzyme Regulates T cell Activity and Mitigates Tumor Growth.Scientific reports · 2019Article
- Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors.Oncology letters · 2019Article
- Genetic Redirection of T Cells for the Treatment of Pancreatic Cancer.Frontiers in oncology · 2019Review
- Role of Chimeric Antigen Receptor T Cell Therapy in Glioblastoma Multiforme.Molecular neurobiology · 2018Review
- Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research.Nature reviews. Gastroenterology & hepatology · 2018Review
- Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice.Medical oncology (Northwood, London, England) · 2018Review
- Prospects of chimeric antigen receptor T cell therapy in ovarian cancer.Medical oncology (Northwood, London, England) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunotherapies are emerging as highly promising approaches for the treatment of cancer. In these approaches, a variety of materials are used to boost immunity against malignant cells. A key component of many of these approaches is functional tumor-specific T cells, but the existence and activity of sufficient T cells in the immune repertoire is not always the case. Recent methods of generating tumor-specific T cells include the genetic modification of patient lymphocytes with receptors to endow them with tumor specificity. These T cells are then expanded in vitro followed by infusion of the patient in adoptive cell transfer protocols. Genes used to modify T cells include those encoding T-cell receptors and chimeric antigen receptors. In this review, we provide an introduction to the field of genetic engineering of T cells followed by details of their use against cancer in the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.